IL22 and inflammatory bowel disease: Additionally, the delivery of IL-22 has shown beneficial effects in the pathology of several animal models of disease including vancomycin resistant enterococcus infections, liver damage, diabetic wounds and inflammatory bowel disease, thus demonstrating its therapeutic potential (Zenewicz et al., 2008; Avitabile et al., 2015; Abt et al., 2016).